BioCentury
ARTICLE | Clinical News

Neuralstem falls on ALS Phase II

March 13, 2015 1:33 AM UTC

Neuralstem Inc. (NYSE-M:CUR) fell $1.37 (37%) to $2.37 on Thursday after reporting that its NSI-566 human neural stem cells slowed disease progression in less than half of patients in a Phase II trial to treat amyotrophic lateral sclerosis.

Neuralstem said the hNSCs slowed the decline in Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) scores in seven of 15 patients (47%). Those deemed responders had an average ALSFRS score of 37 at nine months vs. 14 for non-responders, corresponding to a 7% decline vs. a 65% decline from baseline, respectively. The open-label trial did not contain a control arm. ...